Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Fineline Cube Jan 13, 2026
Company Drug

CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients

Fineline Cube Jan 13, 2026
Company Deals

Henlius Biotech Secures Exclusive Rights to Sermonix’s Lasofoxifene for Breast Cancer Treatment in China

Fineline Cube Jan 11, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a partnership and licensing agreement with...

Company Drug

GenFleet’s SLS009 Receives Fast-Track and Orphan Drug Designations from U.S. FDA for Lymphoma and Leukemia

Fineline Cube Jan 11, 2024

Shanghai-based biotech GenFleet Therapeutics announced that its CDK9 inhibitor, SLS009 (GFH009), has received fast-track and...

Company Deals

GSK’s Acquisition of Aiolos Bio Bolsters Respiratory Medicine Portfolio with AIO-001

Fineline Cube Jan 10, 2024

UK pharmaceutical giant GSK plc (LON: GSK) has announced a deal to acquire Aiolos Bio,...

Company

WuXi AppTec Expands Peptide Manufacturing Capacity with Two New Plants in China

Fineline Cube Jan 10, 2024

WuXi AppTec (HKG: 2359, SHA: 603259), a leading China-based Contract Research, Development, and Manufacturing Organization...

Company Medical Device

Sino Medical Sciences’ HT Supreme Drug-Eluting Stent System Gains Market Approval in Bangladesh

Fineline Cube Jan 10, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical device company, has announced that...

Company Drug

Novartis’s Cosentyx Secures Additional Indication for Psoriatic Arthritis in China

Fineline Cube Jan 10, 2024

Swiss pharmaceutical giant Novartis (SWX: NOVN) has announced that its drug Cosentyx (secukinumab), which targets...

Company Drug

Pfizer and Genmab’s Tivdak Earns Priority Review from FDA for Full Registration

Fineline Cube Jan 10, 2024

The US Food and Drug Administration (FDA) has accepted for priority review a filing from...

Company

International Society for Cell & Gene Therapy Comments on FDA’s CAR-T Investigation

Fineline Cube Jan 10, 2024

The International Society for Cell & Gene Therapy (ISCT) has published a statement addressing the...

Company Hospital

Meizhong Jiahe Medical Debuts on Hong Kong Stock Exchange Below IPO Price

Fineline Cube Jan 10, 2024

China-based Meizhong Jiahe Medical Science & Technology Development Co., Ltd has completed its initial public...

Company Drug Medical Device

AbbVie Launches Continuous Infusion Therapy for Advanced Parkinson’s Disease in EU

Fineline Cube Jan 10, 2024

AbbVie (NYSE: ABBV) has announced the launch of its dopamine replacement therapy, Produodopa (foslevodopa +...

Company Drug

OBI Pharma Gets US FDA Green Light for TROP2 Targeting ADC Cancer Therapy Clinical Study

Fineline Cube Jan 10, 2024

OBI Pharma (4174.TWO), partner to Biosion Inc., has announced that it has received approval from...

Company Deals

Bio-Link Partners with Verdot to Distribute Innovative Bioprocessing Products in China

Fineline Cube Jan 10, 2024

Bio-Link Biological Applied Technologies (Shanghai) Co., Ltd., a leading provider of life sciences industry solutions...

Company Deals

Synvida Raises Nearly RMB 200 Million in Series A Funding to Advance Clinical Studies

Fineline Cube Jan 10, 2024

Synvida, a biotech company incubated by Shanghai Pharma (HKG: 2607, SHA: 601607) and Shanghai Healthcare...

Company Deals Medical Device

Sinocare Partners with Illumina to Localize iScan Chip Scanners for Precision Health Applications

Fineline Cube Jan 10, 2024

Sinocare Inc. (SHE: 300298), a China-based company, has entered into a partnership agreement with U.S....

Company Deals

Johnson & Johnson to Acquire Ambrx Biopharma in a Deal Valued at USD 2 Billion

Fineline Cube Jan 9, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has announced its intention to...

Company Drug

MSD’s Gardasil 9 Receives NMPA Approval for Two-Dose Schedule in Younger Females

Fineline Cube Jan 9, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a prominent pharmaceutical company in the U.S., has...

Company Drug

Astellas’ Zolbetuximab Faces FDA Rejection Due to Manufacturing Facility Deficiencies

Fineline Cube Jan 9, 2024

The US Food and Drug Administration (FDA) has issued a rejection for a filing submitted...

Company Drug

3SBio Inc. Receives NMPA Approval for OTC Minoxidil Foam for Male Hair Loss Treatment

Fineline Cube Jan 9, 2024

3SBio Inc., a leading biopharmaceutical company based in China (HKG: 1530), has announced that it...

Company Deals

MSD to Acquire Harpoon Therapeutics for USD 680 Million, Expanding Its Oncology Pipeline

Fineline Cube Jan 9, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced its...

Company

Eli Lilly Appoints First Female Leader for China Unit with Huzur Devletsah at the Helm

Fineline Cube Jan 9, 2024

Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical corporation in the U.S., has announced...

Posts pagination

1 … 360 361 362 … 609

Recent updates

  • Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes
  • CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients
  • Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk
  • ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform
  • Hengrui’s SHR‑1826 ADC Earns Breakthrough Therapy Designation for c‑Met Overexpressed NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Company Drug

CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients

Company Medical Device

Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk

Company Drug

ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.